Committee on Energy and Commerce U.S. House of Representatives Witness Disclosure Requirement - "Truth in Testimony"

Required by House Rule XI, Clause 2(g)(5)

1.	Your Name:			
	Alexis Geier Horan			
2.	Your Title:			
	Vice President of Government Relations			
3.	The Entity(ies) You are Representing:			
	CleanSlate Addiction Treatment Centers	1	ı	
4.	Are you testifying on behalf of the Federal, or a State or local	Yes	No	
	government entity?		X	
5.	Please list any Federal grants or contracts, or contracts or payments originating with			
	a foreign government, that you or the entity(ies) you represent have received on or			
	after January 1, 2015. Only grants, contracts, or payments related to the subject			
	matter of the hearing must be listed.			
	None			
6.	. Please attach your curriculum vitae to your completed disclosure form.			
Signature:Date:3/18/18				

ALEXIS GEIER HORAN

GOVERNMENT RELATIONS EXECUTIVE

Health policy expert with demonstrated results in strategic planning, policy development, policy analysis, program implementation and project management.

Mission-driven behavioral health policy consultant with repeated success in changing policy in favor of equitable, accessible healthcare. Demonstrated expertise in health policy strategy, health policy analysis, legislative and regulatory proposal development, and program development, implementation and evaluation.

Areas of Expertise:

- Policy Development and Execution
- Strategic Planning and Evaluation
- Program
 Implementation and Evaluation

PROFESSIONAL EXPERIENCE

CLEANSLATE ADDICTION TREATMENT CENTERS, WASHINGTON, DC

2016 - Present

Vice President of Government Relations

Build and direct a government relations department in support of company's goals of improved patient access to opioid and alcohol addiction treatment, corporate branding and corporate growth. Create strategy for and direct federal and state government relations programs that establish CleanSlate brand with patients, providers, policy makers and key influencers; support company's national expansion in new and existing markets; and drive development of state and federal policies that increase access to high quality, medical treatment of substance use disorders. Monitor for and respond to policies that impede delivery of pharmacotherapy treatment for opioid and alcohol addiction. Work with state and federal legislators to draft new or improve upon existing policy that promotes patient access to evidence-based out-patient addiction treatment. Represent CleanSlate external relations priorities and progress on executive leadership cabinet. Manage state and federal government relations consultants.

Selected Achievements:

- Established government relations presence in each state (eight) where CleanSlate actively treats patients.
- Worked with state legislators to improve upon draft opioid bills, to address barriers to delivery of outpatient opioid addiction treatment and direct state opioid funding to evidence-based opioid treatment providers.
- Supported CleanSlate clinical leadership, in developing a proposal to one state for how CleanSlate would meet newly established office-based opioid treatment program licensing requirements.

DEPARTMENT OF HEALTH AND HUMAN SERVICES, WASHINGTON, DC

2015 - 2016

Expert Consultant to the Office of Assistant Secretary for Planning and Evaluation (ASPE), Division of Aging, Disability and Long-term Care Policy

Lead implementation of the Department's Opioid Initiative to address national opioid addiction epidemic, with a particular focus on efforts to improve access to treatment. Support implementation of Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), including the development of consumer and insurer guidance regarding consumer rights and benefits coverage. Primary responsibilities relevant to the Opioid Initiative, MHPAEA and other behavioral health programs: advising Department leadership on technical issues and research findings and developing legislative, regulatory and budgetary proposals relevant to the Department's Opioid Initiative; assisting development of rulemaking and Department and Administration policy proposals that advance addiction and mental health treatment; providing senior officials technical assistance on legislation, regulations, Congressional testimony, reports and briefs; and developing research ideas and conducting research projects and program evaluations that improve upon behavioral health program design, implementation and outcomes. Also responsible for intra-departmental consultation on the intersection of addiction and health and human services policies including homelessness, aging, disabled and other vulnerable populations; drafting Secretary/Assistant Secretary letters in response to Congressional and stakeholder inquiries and requests; and collaborating with Agencies and external stakeholders to coordinate and communicate Department policy priorities and activities.

Selected Achievements:

- Development of rule to increase physician prescribing limit for buprenorphine-based medicationassisted treatment,
- Development of a proposal for President's FY 2017 Budget, to establish a demonstration to assess the feasibility of authorizing nurse practitioners and physician assistants to prescribe buprenorphine for the treatment of opioid use disorder,
- Development of President's FY 2017 budget proposals to address opioid use disorder treatment gap,
- Represent ASPE on Prescription Drug, Marijuana and Quality Improvement Subcommittees of HHS
 Behavioral Health Coordinating Council; Centers for Medicare and Medicaid Services-convened
 Behavioral Health Affinity Group; White House Mental Health and Substance Use Disorder Parity Task
 Force; Planning Committee for Surgeon General's Report on Alcohol, Drugs and Health; and Federal
 Steering Committee responsible for development of clinical treatment guideline for management of
 opioid-dependent pregnant and parenting women.
- Development of research projects that will better inform policies that promote addiction treatment workforce development, improve patient access to addiction treatment pharmacotherapy and reduce barriers to provider and payer adoption of addiction treatment best practices.

AMERICAN SOCIETY OF ADDICTION MEDICINE, CHEVY CHASE, MD

2004 - 2015

Sr. Director of Government Relations and Clinical Practice

(Government Relations Associate, Director of Government Relations)

Advance the Society's mission to increase access to and improve the quality of addiction treatment through advocacy. Expand government relations (GR) program, public policy development, practice improvement and performance measurement activities and Congressional and coalition relationships. Draft regulatory comments, testimony and all other written and oral policy and advocacy communications on behalf of the Society's leadership. Manage public relations regarding the Society's positions on policies affecting addiction prevention and treatment, health care reimbursement and payment reform, addiction best practices and clinical guidelines and all other general inquiries. Function as Society liaison to Congressional staff, government agencies, state and specialty medical associations, patient groups, and coalitions. Organize annual legislative advocacy events on Capitol Hill and other state and federal grassroots lobbying efforts. Support board-appointed committees related to advocacy, public policy, quality/practice improvement and communications issue areas. Recruit and supervise GR staff, interns and consultants, annual GR budget and ongoing member communications regarding advocacy and public policy. Regularly collaborate with the society's Board of Directors, state chapter leaders and corporate roundtable members, as well as with the Executive, Professional Development, and Fundraising Departments.

Selected Achievements:

- Lead a Board-initiated task force to address payer policies limiting access to opioid-addiction pharmacotherapies, including research, legal review, stakeholder briefings and community outreach.
- Supervised a multi-stakeholder effort to develop performance measures and clinical standards for addiction medicine physician specialists as well as practice guidelines on the use of pharmacotherapies to treat opioid dependence.
- Created a members' advocacy program focused on developing grassroots core competencies among ASAM members and state affiliates, branding ASAM as a leader in addiction medicine, science and policy issues, and expanding access to high quality addiction treatment.
- Commissioned first government relations strategic plan to guide Board of Directors' goals for growing and improving the organization's government relations and public policy programs.
- Drove member advocacy efforts that resulted in equitable insurance coverage for addiction and mental health benefits, among other addiction treatment and prevention-friendly provisions, in the Patient Protection and Affordable Care Act (PL, 111-148).
- Directed member advocacy push that resulted in passage of major addiction and mental health insurance reform (Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act, PL-110-343).
- Coordinated a board directed initiative that resulted in a change in federal law (DATA 2000, Public Law 106-310) that allows physicians with a DEA waiver to treat up to 100 opiate-dependant patients in an office-based setting, whereas the original language limited physicians in group practices to 30 patients.

ADDITIONAL EXPERIENCE			
American Institute of Chemical Engineers, New York, NY Development Manager, Career Services Associate	2001 - 2003		
New York Business Forums, New York, NY <i>Manager, Research</i>	1999 - 2001		
ORBIS INTERNATIONAL, NEW YORK, NY Development Coordinator	1998 - 1999		
OPERATION SMILE, NORFOLK, VA Youth Development Coordinator	1996 - 1998		

EDUCATION

Master of Public Policy, George Washington University, Washington, DC, 2005

Bachelor of Science in Biology and Sociology, Boston College, Boston, MA, 1996

EXTENDED LEARNING

ASAE Government Relations School, 2006, 2008 WGR Connect to Congress Mini-Session, 2014 Office of Personnel Management Center for Leadership Development course, "Leadership Skills for Non-Supervisors, 2016

AWARDS AND RECOGNITION

US Department of Health and Human Services Secretary's Award for Distinguished Service, 2016 American Society of Addiction Medicine's Presidential Award, 2015

RESEARCH AND PUBLICATIONS

Thomas, C.P., et al. (2017). Prescribing patterns of buprenorphine waivered physicians. *Drug & Alcohol Dependence, Volume 181*, 213 – 218.